CD8A and melanoma: Interestingly, mice fed with UroA-enriched diet and engrafted with B16 melanoma cells and treated with anti-PD-1 immunotherapy did not display better tumor control (Fig. 1F), confirming that UroA supplementation did not modulate CD8+ T-cell state within the TME in the B16 melanoma.